All In Biotech

Drug Trial Radar · NCT06806852

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

A Phase Ib Open Label Randomised Clinical Trial to Evaluate Safety and Efficacy of BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Compared With Pembrolizumab Monotherapy for the First-line Treatment of Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

91

Actual

Start

May 14, 2025

Primary completion

Aug 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Feb 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with head and neck cancer. The purpose of this study is to find out whether combining different study medicines makes tumors shrink in people with head and neck cancer. The tested medicines in this study are antibodies that act in different ways against cancer. BI 770371 and pembrolizumab may help the immune system fight cancer. Cetuximab blocks growth signals and may prevent the tumor from growing. Participants are put into 3 groups randomly. Each group receives a different combination of study medicines. All study medicines are given as an infusion into a vein at the study site. Participants can stay in the study as long as they benefit from treatment. Doctors regularly check the size of the tumor and check whether it has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Head and Neck Squamous Cell Carcinoma

Interventions

  • BI 770371Drug

    BI 770371

  • PembrolizumabDrug

    Pembrolizumab

  • CetuximabDrug

    Cetuximab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response (OR) with confirmationTime frame: Up to 27 months

Locations

51 sites in 22 countries. Site status is shown where the registry gives one.

  • Norton Cancer Institute, Downtown

    Louisville, Kentucky

  • M Health Fairview Clinics and Surgery Center - Minneapolis

    Minneapolis, Minnesota

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Gosford Hospital

    Gosford, New South Wales, Australia

  • Andrew Love Cancer Centre

    Geelong, Victoria, Australia

  • Hospital de Amor

    Barretos, Brazil

  • Liga Norte Riograndense contra o cancer

    Natal, Brazil

  • Fundaçao Faculdade Regional de Medicina de Sao Jose do Rio Preto

    São José do Rio Preto, Brazil

  • MBAL Sveta Sofia

    Sofia, Bulgaria

  • CTR Oscar Lambret

    Lille, France

  • CTR Leon Berard

    Lyon, France

  • HOP Timone

    Marseille, France

  • Institut Gustave Roussy

    Villejuif, France

  • ARENSIA Exploratory Medicine LLC

    Tbilisi, Georgia

  • Städtisches Klinikum Braunschweig gGmbH

    Braunschweig, Germany

  • Universitätsklinikum Jena

    Jena, Germany

  • Universität Leipzig

    Leipzig, Germany

  • Universitätsklinikum Ulm

    Ulm, Germany

  • Semmelweis University

    Budapest, Hungary

  • Clinexpert Gyongyos

    Gyöngyös, Hungary

  • Istituto Scientifico Romagnolo

    Meldola (FC), Italy

  • Azienda Ospedaliera Universitaria Integrata Verona

    Verona, Italy

  • Hokkaido University Hospital

    Hokkaido, Sapporo, Japan

  • Kobe University Hospital

    Hyogo, Kobe, Japan

  • Kansai Medical University Hospital

    Osaka, Hirakata, Japan

  • Shizuoka Cancer Center

    Shizuoka, Sunto-gun, Japan

  • Japanese Foundation for Cancer Research

    Tokyo, Koto-ku, Japan

  • Centro Oncologico Personalizado

    México, Mexico

  • Instituto Nacional de Cancerologia

    México, Mexico

  • Unidad Clinica Farmacologica Bioemagno

    Mexico City, Mexico

  • Centro Oncológico Internacional

    Tlajomulco de Zuñiga, Mexico

  • ARENSIA Exploratory Medicine

    Chisinau, Moldova

  • Center of Oncology of the Lublin Region St. Jana z Dukli

    Lublin, Poland

  • "Prof. Dr. Alexandru Trestioreanu" Oncology Institut

    Bucharest, Romania

  • National University Hospital-Singapore-22806

    Singapore, Singapore

  • Severance Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • The Catholic University of Korea, St.Vincent's Hospital

    Suwon, South Korea

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Cantonspital Aarau

    Aarau, Switzerland

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.